Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception

Premila Wencesiaus Ashok, Haitham Hamoda, G. M. M. Flett, Alexander Allan Templeton

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To compare side effects, women's acceptance and satisfaction with mifepristone (100 mg) versus the Yuzpe regimen for emergency contraception (EC). Methods: A total of 1000 women requesting EC within 72 h of unprotected intercourse were randomized to receive mifepristone 100 mg or the standard Yuzpe regimen. Outcome measures included patient acceptability and satisfaction. Results: A total of 620 (62%) questionnaires were returned, 64% in the mifepristone group and 60% in the Yuzpe group. Mifepristone was better tolerated than the Yuzpe regimen. The rates of nausea (P<0.0001), abdominal pain (P=0.001), tiredness (P<0.0001), lethargy (P=0.001), hot flushes (P<0.0001) and dizziness (P<0.0001) were all significantly higher in women given the Yuzpe regimen compared to those who received mifepristone. Of these 94% and 80% in the mifepristone and Yuzpe groups, respectively, were satisfied with treatment (P<0.0001). Of women in the mifepristone group, 56% (181/321) had used the Yuzpe regimen of EC in the past and of these, 93.6% (161/172) indicated they would use mifepristone in the future. A total of four women in the Yuzpe group had mifepristone in the past and all four said they would use mifepristone in the future. Conclusion: Mifepristone has high patient acceptability and few side effects compared to the standard Yuzpe regimen for EC. (C) 2004 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)188-193
Number of pages5
JournalInternational Journal of Gynecology & Obstetrics
Volume87
DOIs
Publication statusPublished - 2004

Keywords

  • emergency contraception
  • postcoital contraception
  • mifepristone
  • Yuzpe
  • acceptability
  • POSTCOITAL CONTRACEPTION
  • ETHINYL ESTRADIOL
  • NORGESTREL
  • OVULATION
  • RU-486
  • TRIAL

Cite this

Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception. / Ashok, Premila Wencesiaus; Hamoda, Haitham; Flett, G. M. M.; Templeton, Alexander Allan.

In: International Journal of Gynecology & Obstetrics, Vol. 87, 2004, p. 188-193.

Research output: Contribution to journalArticle

@article{e0c243f9a4ce44a7b619f844c41349f0,
title = "Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception",
abstract = "Objective: To compare side effects, women's acceptance and satisfaction with mifepristone (100 mg) versus the Yuzpe regimen for emergency contraception (EC). Methods: A total of 1000 women requesting EC within 72 h of unprotected intercourse were randomized to receive mifepristone 100 mg or the standard Yuzpe regimen. Outcome measures included patient acceptability and satisfaction. Results: A total of 620 (62{\%}) questionnaires were returned, 64{\%} in the mifepristone group and 60{\%} in the Yuzpe group. Mifepristone was better tolerated than the Yuzpe regimen. The rates of nausea (P<0.0001), abdominal pain (P=0.001), tiredness (P<0.0001), lethargy (P=0.001), hot flushes (P<0.0001) and dizziness (P<0.0001) were all significantly higher in women given the Yuzpe regimen compared to those who received mifepristone. Of these 94{\%} and 80{\%} in the mifepristone and Yuzpe groups, respectively, were satisfied with treatment (P<0.0001). Of women in the mifepristone group, 56{\%} (181/321) had used the Yuzpe regimen of EC in the past and of these, 93.6{\%} (161/172) indicated they would use mifepristone in the future. A total of four women in the Yuzpe group had mifepristone in the past and all four said they would use mifepristone in the future. Conclusion: Mifepristone has high patient acceptability and few side effects compared to the standard Yuzpe regimen for EC. (C) 2004 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.",
keywords = "emergency contraception, postcoital contraception, mifepristone, Yuzpe, acceptability, POSTCOITAL CONTRACEPTION, ETHINYL ESTRADIOL, NORGESTREL, OVULATION, RU-486, TRIAL",
author = "Ashok, {Premila Wencesiaus} and Haitham Hamoda and Flett, {G. M. M.} and Templeton, {Alexander Allan}",
year = "2004",
doi = "10.1016/j.ijgo.2004.06.012",
language = "English",
volume = "87",
pages = "188--193",
journal = "International Journal of Gynecology & Obstetrics",
issn = "0020-7292",
publisher = "Wiley",

}

TY - JOUR

T1 - Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception

AU - Ashok, Premila Wencesiaus

AU - Hamoda, Haitham

AU - Flett, G. M. M.

AU - Templeton, Alexander Allan

PY - 2004

Y1 - 2004

N2 - Objective: To compare side effects, women's acceptance and satisfaction with mifepristone (100 mg) versus the Yuzpe regimen for emergency contraception (EC). Methods: A total of 1000 women requesting EC within 72 h of unprotected intercourse were randomized to receive mifepristone 100 mg or the standard Yuzpe regimen. Outcome measures included patient acceptability and satisfaction. Results: A total of 620 (62%) questionnaires were returned, 64% in the mifepristone group and 60% in the Yuzpe group. Mifepristone was better tolerated than the Yuzpe regimen. The rates of nausea (P<0.0001), abdominal pain (P=0.001), tiredness (P<0.0001), lethargy (P=0.001), hot flushes (P<0.0001) and dizziness (P<0.0001) were all significantly higher in women given the Yuzpe regimen compared to those who received mifepristone. Of these 94% and 80% in the mifepristone and Yuzpe groups, respectively, were satisfied with treatment (P<0.0001). Of women in the mifepristone group, 56% (181/321) had used the Yuzpe regimen of EC in the past and of these, 93.6% (161/172) indicated they would use mifepristone in the future. A total of four women in the Yuzpe group had mifepristone in the past and all four said they would use mifepristone in the future. Conclusion: Mifepristone has high patient acceptability and few side effects compared to the standard Yuzpe regimen for EC. (C) 2004 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

AB - Objective: To compare side effects, women's acceptance and satisfaction with mifepristone (100 mg) versus the Yuzpe regimen for emergency contraception (EC). Methods: A total of 1000 women requesting EC within 72 h of unprotected intercourse were randomized to receive mifepristone 100 mg or the standard Yuzpe regimen. Outcome measures included patient acceptability and satisfaction. Results: A total of 620 (62%) questionnaires were returned, 64% in the mifepristone group and 60% in the Yuzpe group. Mifepristone was better tolerated than the Yuzpe regimen. The rates of nausea (P<0.0001), abdominal pain (P=0.001), tiredness (P<0.0001), lethargy (P=0.001), hot flushes (P<0.0001) and dizziness (P<0.0001) were all significantly higher in women given the Yuzpe regimen compared to those who received mifepristone. Of these 94% and 80% in the mifepristone and Yuzpe groups, respectively, were satisfied with treatment (P<0.0001). Of women in the mifepristone group, 56% (181/321) had used the Yuzpe regimen of EC in the past and of these, 93.6% (161/172) indicated they would use mifepristone in the future. A total of four women in the Yuzpe group had mifepristone in the past and all four said they would use mifepristone in the future. Conclusion: Mifepristone has high patient acceptability and few side effects compared to the standard Yuzpe regimen for EC. (C) 2004 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

KW - emergency contraception

KW - postcoital contraception

KW - mifepristone

KW - Yuzpe

KW - acceptability

KW - POSTCOITAL CONTRACEPTION

KW - ETHINYL ESTRADIOL

KW - NORGESTREL

KW - OVULATION

KW - RU-486

KW - TRIAL

U2 - 10.1016/j.ijgo.2004.06.012

DO - 10.1016/j.ijgo.2004.06.012

M3 - Article

VL - 87

SP - 188

EP - 193

JO - International Journal of Gynecology & Obstetrics

JF - International Journal of Gynecology & Obstetrics

SN - 0020-7292

ER -